Search

Search Constraints

You searched for: Author/Creator Pignata, Sandro

Search Results

1. 1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer. Issue 6 (November 2017)

2. 2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205. (20th October 2022)

3. 2022-RA-1433-ESGO Reproductive outcomes after conservative treatment in malignant ovarian germ cell tumors (MOGCTs) patients: a MITO-9 study. (20th October 2022)

4. 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. (20th October 2022)

5. 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22. (20th October 2022)

6. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician's choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). (20th October 2022)

7. 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. (20th October 2022)

8. 2022-RA-873-ESGO Validation study of the 'NOGGO-GIS ASSAY' based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial. (20th October 2022)

9. 2022-RA-883-ESGO Rare Cancers in Gynecologic Oncology, ENGOT initiative for a European Registry. (20th October 2022)

10. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer. (3rd January 2021)